Hormone receptor positive HER2 negative breast cancer
Not yet recruitingStudy of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA
Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AbemaciclibCamizestrant
France- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:Unicancer





